In a recent Federal Register notice, the National Institutes of Health (NIH) has announced its intent to grant an exclusive patent license on chimeric antigen receptor (CAR) therapies for the treatment of certain cancers to ElevateBio, a company located in… Continue Reading
On June 8, 2018 the Cámara de Diputados of the Chilean Congress overwhelmingly passed a resolution calling on the Ministry of Health to proceed with compulsory licenses on patents covering hepatitis C virus (HCV) drugs. Resolution No. 68, passed with… Continue Reading
These were KEI comments to USTR regarding PhRMA’s efforts to target Malaysia as a Priority Foreign Country for issuing a compulsory license on sofosbuvir patents. Malaysia.14March2018.KEI.USTR.Special 301 March 14, 2018 The Honorable Robert Lighthizer United States Trade Representative Executive Office… Continue Reading
In the attached letter dated March 14, 2018 to Secretary of the Department of Health and Human Services (DHHS) Alex Azar, KEI is asking for an investigation into a failure to report NIH funding on US patent 7,964,580. This is… Continue Reading